At 48 weeks, 57 percent of the Fortovase
recipients had undetectable HIV RNA viral load levels below 400 copies; however, only 38 percent of the Invirase recipients had undetectable viral load levels.
Roche has taken this action due to a significant decline in the demand for Fortovase as well as in response to the updated HIV treatment guidelines from the U.
The Fortovase formulation of saquinavir no longer meets the demands of convenience and tolerability expected by patients today.
Protease Inhibitors Nucleotide Reverse Agenerase (generic name: amprenavir) Transcriptase Inhibitor Crixivan (indinavir) Viread (tenofovir, PMPA) Fortovase (saquinavir) Kaletra (lopinavir plus ritonavir) Nucleoside Reverse Norvir (ritonavir) Transcriptase Inhibitors Viracept (nelfinavir) Combivir (AZT plus 3TC) Epivir (lamivudine, also Nonnucleoside Reverse known as 3TC) Transcriptase Inhibitors Hivid (zalcitabine, ddC) Rescriptor (delavirdine) Retrovir (zidovudine, AZT) Sustiva (efavirenz) Trizivir (abacavir plus AZT plus 3TC) Viramune (nevirapine) Videx (didanosine, ddl) Zerit (stavudine, d4T) Ziagen (abacavir)
COLUMN A COLUMN B Crixivan Combivir Kaletra Retrovir plus Epivir Norvir plus Fortovase Retrovir plus Videx Norvir plus Kaletra Trizivir Sustiva Zerit plus Epivir Viracept Zerit plus Videx
Agenerase amprenavir Combivir [AZT+3TC] Crixivan indinavir Epivir lamivudine (3TC) Fortovase
saquinavir Hivid zalcitabine (ddC) Kaletra lopinavir/ritonavir Norvir ritonavir Rescriptor delavirdine Retrovir zidovudine (AZT) Sustiva efavirienz Trizivir [abacavir+AZT+3TC] Videx didanosine (ddI) Viracept nelfinavir Viramune nevirapine Viread tenofovir DF Zerit stavudine (d4T) Ziagen abacavir
Fischer was Medical Director for Hoffmann-LaRoche's Virology Group, where he was involved in the launch of INVIRASE and developed FORTOVASE
, protease inhibitors for the treatment of HIV.
New INVIRASE(R) 500 mg tablet reduces pill count and diminishes clinical demand for FORTOVASE
Invirase capsules and Fortovase
soft gelatin capsules are not bioequivalent and cannot be used interchangeably.
Medications developed by Roche for HIV include Fortovase
and Invirase (two formulations of saquinavir), administered in combination with ritonavir, and Viracept (nelfinavir).
There are two formulations of saquinavir; Fortovase
is a formulation that can also be taken without ritonavir, three times daily.
Patients who received boosted saquinavir in the MaxCmin2 study were switched to the Invirase formulation if they experienced gastrointestinal upset with the Fortovase
with ritonavir was studied in a heterogeneous population of 148 HIV-infected patients.
The most frequently reported adverse events at least possibly related to treatment with Fortovase
and of at least moderate intensity -- observed in trials evaluating the approved 1200 mg three-times-daily dosing regimen -- include nausea (17.
The new formulation of saquinavir is smaller in size than the current 200 mg Invirase and Fortovase
capsules and could reduce pill burden for the twice-daily boosted saquinavir regimen by half (from six pills to three).